A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
Ontology highlight
ABSTRACT:
DISEASE(S): Colorectal Carcinoma,Colorectal Neoplasms Malignant,Colorectal Cancer Metastatic,Colorectal Neoplasms,Metastatic, Previously-treated, Microsatellite-stable Colorectal Carcinoma,Neoplasms
PROVIDER: 2308907 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:Gut microbiome significantly influences immunotherapy responses in colorectal cancer (CRC) treatment. While individual enterobacteria have been identified as enhancers of anti-PD-1/anti-PD-L1 therapy, the synergistic effects of multiple enterobacteria remain underexplored. To fill the gap, we introduced Tumor-Suppressing Multi-Enterobacteria (TSME), a consortium of nine beneficial intestinal probiotic strains, and investigated its impact on the anti-PD-1/anti-PD-L1 therapy for microsatellite stable (MSS) CRC. Using a tumor-bearing mouse model and genomic sequencing techniques, our research demonstrated that TSME significantly improved therapy efficacy by optimizing tumor immune microenvironment. Specifically, the addition of TSME notably increased CD8+ T infiltration, modulated cytokine profiles, and up-regulated crucial immune-related pathways, including TNF and JAK-STAT. Additionally, TSME altered intestinal microbial composition, enriching beneficial bacteria such as Akkermansia and Alistipes. These findings suggest that the well-engineered multi-enterobacteria could significantly enhance the effectiveness of immunotherapy for MSS CRC by synergistically modulating the immune and microbial landscapes.
2026-04-26 | GSE271663 | GEO
Project description:Microsatellite-stable (MSS) colorectal cancers (CRC) display inherent insensitivity to immune checkpoint blockade, and the pivotal mechanisms responsible for this immunotherapeutic resistance have not been fully clarified. Here, we demonstrate that MSS CRC elicit CD8⁺ T cell senescence to mediate immune evasion, which distinguishes them from microsatellite-instable (MSI) CRC. We further identify SEMA3A, a secreted protein markedly upregulated in MSS CRC, as a crucial mediator that directly drives CD8⁺ T cell senescence. Mechanistically, SEMA3A engages neuropilin-1 (NRP1) to hijack JAK1 signaling, which blunts cytokine-triggered STAT3 phosphorylation and ultimately reduces TCF1 expression. At the molecular level, TCF1 directly binds to and transcriptionally represses senescence-associated genes. The loss of TCF1 in CD8⁺ T cells infiltrating MSS CRC tumors abolishes this transcriptional repression, thereby inducing CD8⁺ T cell senescence and conferring refractoriness to PD-L1 blockade. In syngeneic murine models of MSS CRC, dual neutralization of SEMA3A and PD-L1 restores TCF1 expression, rescues CD8⁺ T cells from senescence, and significantly improves immunotherapy efficacy. Clinical data corroborate that SEMA3A expression is positively correlated with CD8⁺ T cell senescence and serves as a reliable prognostic biomarker for inferior immunotherapy responses in patients with MSS CRC. Collectively, this study delineates a SEMA3A/NRP1-JAK1-STAT3-TCF1 signaling axis that governs CD8⁺ T cell senescence and tumor immune evasion in MSS CRCs, validating SEMA3A as a promising predictive biomarker and druggable therapeutic target for this immunotherapy-refractory MSS CRC.
2026-08-17 | GSE343928 | GEO
Project description:Microsatellite-stable (MSS) colorectal cancers (CRC) display inherent insensitivity to immune checkpoint blockade, and the pivotal mechanisms responsible for this immunotherapeutic resistance have not been fully clarified. Here, we demonstrate that MSS CRC elicit CD8⁺ T cell senescence to mediate immune evasion, which distinguishes them from microsatellite-instable (MSI) CRC. We further identify SEMA3A, a secreted protein markedly upregulated in MSS CRC, as a crucial mediator that directly drives CD8⁺ T cell senescence. Mechanistically, SEMA3A engages neuropilin-1 (NRP1) to hijack JAK1 signaling, which blunts cytokine-triggered STAT3 phosphorylation and ultimately reduces TCF1 expression. At the molecular level, TCF1 directly binds to and transcriptionally represses senescence-associated genes. The loss of TCF1 in CD8⁺ T cells infiltrating MSS CRC tumors abolishes this transcriptional repression, thereby inducing CD8⁺ T cell senescence and conferring refractoriness to PD-L1 blockade. In syngeneic murine models of MSS CRC, dual neutralization of SEMA3A and PD-L1 restores TCF1 expression, rescues CD8⁺ T cells from senescence, and significantly improves immunotherapy efficacy. Clinical data corroborate that SEMA3A expression is positively correlated with CD8⁺ T cell senescence and serves as a reliable prognostic biomarker for inferior immunotherapy responses in patients with MSS CRC. Collectively, this study delineates a SEMA3A/NRP1-JAK1-STAT3-TCF1 signaling axis that governs CD8⁺ T cell senescence and tumor immune evasion in MSS CRCs, validating SEMA3A as a promising predictive biomarker and druggable therapeutic target for this immunotherapy-refractory MSS CRC.
2026-08-17 | GSE343811 | GEO
Project description:The BRAF inhibitor encorafenib and anti-EGFR antibody cetuximab modestly improve survival for patients with microsatellite stable (MSS) BRAFV600E metastatic colorectal cancer (mCRC), characterized by higher immune activation than MSS BRAFwild-type CRC. In this phase I/II study (NCT04017650) of 26 participants with MSS BRAFV600E mCRC who received encorafenib, cetuximab, and anti-PD-1 antibody nivolumab, we report an overall response rate of 50% (95% confidence interval (CI) 29-71) and median progression-free survival of 7.4 months (95% CI, 5.6-9.6). Transcriptomic profiling of pretreatment biopsies and extracellular vesicle RNA (evRNA) isolated from plasma show enrichment of non-canonical MAP kinase signaling and immune activation signatures for responders. Complement pathway activation enriches in non-responder biopsies. On serial evRNA profiling, decreased MAPK signature and increased interferon gamma response signature associate with sustained treatment benefit. MSS BRAFV600E mCRC with baseline MAP kinase activation and immune activation signatures may benefit from the triple combination but not with complement pathway activation.
2025-07-21 | GSE302922 | GEO
Project description:The BRAF inhibitor encorafenib and anti-EGFR antibody cetuximab modestly improve survival for patients with microsatellite stable (MSS) BRAFV600E metastatic colorectal cancer (mCRC), characterized by higher immune activation than MSS BRAFwild-type CRC. In this phase I/II study (NCT04017650) of 26 participants with MSS BRAFV600E mCRC who received encorafenib, cetuximab, and anti-PD-1 antibody nivolumab, we report an overall response rate of 50% (95% confidence interval (CI) 29-71) and median progression-free survival of 7.4 months (95% CI, 5.6-9.6). Transcriptomic profiling of pretreatment biopsies and extracellular vesicle RNA (evRNA) isolated from plasma show enrichment of non-canonical MAP kinase signaling and immune activation signatures for responders. Complement pathway activation enriches in non-responder biopsies. On serial evRNA profiling, decreased MAPK signature and increased interferon gamma response signature associate with sustained treatment benefit. MSS BRAFV600E mCRC with baseline MAP kinase activation and immune activation signatures may benefit from the triple combination but not with complement pathway activation.
2025-07-21 | GSE302921 | GEO
Project description:Cancer immunotherapy with immunostimulatory antibodies targeting the CTLA-4 or PD-1/PD-L1 pathways has demonstrated its efficacy in variable proportions of cancer. For metastatic colorectal cancer (mCRC) it appeared that only the small subgroup of patients with MSI-H tumors (microsatellite instability-high phenotype) had a clinically meaningful response to the anti-PD-1- L1 antibodies. In the majority group of non-MSI-H CRC (90-95% of patients), current research expect that additional means would be able to render the tumor "immunogenic" (like MSI-H CRC) and increase the intratumoral immune infiltrate which is the prerequisite to observe a benefit from PD1-PD-L1 inhibitors. Combinations of immune checkpoint inhibitors and procedures that increase intratumoral immune responses, such as targeted therapy, are actively explored.
| 2279295 | ecrin-mdr-crc
Project description:Microsatellite stable (MSS) colorectal cancer (CRC) is often characterized as a "cold" tumor, exhibiting minimal responsiveness to monotherapy with PD-1 antibodies. The underlying mechanisms of this intrinsic unresponsiveness to immunotherapy have been elusive. Here, we report that cathepsin D (CTSD) is highly expressed in MSS CRC, significantly contributing to its resistance to immunotherapy. Specifically, CTSD facilitates immune evasion by shielding cancer cells from cytotoxic T-cell-mediated killing. Mechanistically, as a protease, CTSD interacts with the α2 domain of the major histocompatibility complex class I (MHC-I) molecule via its catalytic domain's light chain, promoting the degradation of MHC-I through lysosomal pathways and disrupting the recycling of MHC-I to the cell surface. Notably, deletion or pharmacological inhibition of CTSD with pepstatin A prevents this immune evasion and enhances the efficacy of anti-PD-1 antibodies. Collectively, these findings highlight the role of CTSD in immune evasion and provide a compelling rationale for the development of a novel combination therapy involving CTSD inhibition and anti-PD-1 immunotherapy in CRC.
2025-10-18 | GSE306871 | GEO
Project description:Immune checkpoint blockade has limited efficacy in microsatellite stable (MSS) colorectal (CRC) and pancreatic (PDAC) cancer. Preclinical models have demonstrated the use of radiation to activate the innate immune response and stimulate responsiveness to immune checkpoint blockade. Here, we describe a Phase 2 trial of radiation therapy combined with combined anti-CTLA4 (ipilimumab) and anti-PD1 (nivolumab) antibodies in MSS CRC and PDAC. In the per protocol analysis disease control rate was 37% (10/27) in CRC and 29% (5/17) in PDAC with an overall response rate of 15% (4/27) and 18% (3/17), respectively. Whole exome and RNA sequencing of biopsies from 17 patients revealed low tumor mutational burden in all tumors, but a notable upregulation of interferon stimulated genes with concordant high expression of multiple repeat RNA transcripts in responders. Altogether, this study provides foundational human proof of concept of radiation with combination immune checkpoint blockade therapy in otherwise immunotherapy resistant cancers.
2021-07-06 | GSE179351 | GEO
Project description:Microsatellite-stable (MSS) colorectal cancers (CRC) are largely unresponsive to immune checkpoint inhibition (ICI). The MAYA trial used temozolomide (TMZ) in MGMT-silenced MSS mCRC, hypothesizing that TMZ-induced hypermutation could sensitize tumors to ICI; the primary endpoint was met, showing durable responses with TMZ plus ipilimumab and nivolumab. We perform integrated spatial, transcriptomic, and immune profiling of longitudinal tumor and blood samples from patients treated on the MAYA trial. Post-TMZ increases in tumor mutational burden associate with improved progression-free survival. Spatial profiling demonstrates that clinical benefit is greatest in permissive tumor microenvironments. Responders exhibit enrichment of cytotoxic T cells across tumor and stromal compartments, whereas non-responders display heterogeneous cellular neighborhoods, with fibroblasts in close spatial proximity to T cells, consistent with barriers to immune mediated clearance. Longitudinal peripheral immune profiling shows that early upregulation of TIGIT and PD-1 following TMZ exposure predicts resistance. Together, these findings indicate that both mutational evolution and spatial immune architecture contribute to immune sensitization in MGMT-silenced MSS CRC.
2026-03-27 | GSE326101 | GEO
Project description:Treatment with immune checkpoint inhibitors in colorectal cancer (CRC) has largely benefited patients with microsatellite instability–high (MSI-H) and not the larger proportion of patient with microsatellite-stable (MSS) tumors. This clinical dichotomy has fueled the view that high mutational burden is the dominant driver of tumor immunogenicity and that MSS CRC fails to respond because it is “antigen poor”. To directly test this premise and define the origins of presented tumor antigens, we integrated HLA class I immunopeptidomics and matched RNA-seq from 26 primary CRC tumors spanning MSI-H and MSS subtypes. Using patient-specific canonical and cancer-specific proteogenomic databases, we identified 115,292 unique MHC-associated peptides (MAPs) across 61 HLA alleles, with a mean of 9,292 MAPs per tumor and no significant difference in MAP counts between MSI-H and MSS tumors. In toto, we identified 266 tumor antigens, all coded by unmutated genomic sequences, comprising 70 aberrantly expressed tumor-specific antigens (aeTSAs) and 196 tumor-associated antigens (TAAs). In our cohort, MSS tumors presented more TAAs and a comparable number of aeTSAs per tumor relative to MSI-H tumors. In TCGA-COAD stratified analyses (483 tumors), MSS tumors yielded more presentable aeTSAs and TAAs per patient than MSI-H tumors. Across both subtypes, aeTSAs arose predominantly from intronic translation, UTR usage, retroelement activation, and germline-like transcription, including recurrent aeTSAs from PIWIL1, L1TD1, and endogenous retroviral loci. Together, these data demonstrate that MSS CRC is not antigen poor and highlight non-canonical translation as a major, previously underappreciated contributor to the CRC immunopeptidome.
2026-05-26 | GSE312236 | GEO